vs
ADMA BIOLOGICS, INC.（ADMA）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
ADMA BIOLOGICS, INC.的季度营收约是RE/MAX Holdings, Inc.的2.0倍（$139.2M vs $71.1M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs 2.0%，领先33.5%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs -1.8%），ADMA BIOLOGICS, INC.自由现金流更多（$34.6M vs $33.5M），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs -4.7%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
ADMA vs RMAX — 直观对比
营收规模更大
ADMA
是对方的2.0倍
$71.1M
营收增速更快
ADMA
高出20.2%
-1.8%
净利率更高
ADMA
高出33.5%
2.0%
自由现金流更多
ADMA
多$1.1M
$33.5M
两年增速更快
ADMA
近两年复合增速
-4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $71.1M |
| 净利润 | $49.4M | $1.4M |
| 毛利率 | 63.8% | — |
| 营业利润率 | 45.1% | 13.1% |
| 净利率 | 35.5% | 2.0% |
| 营收同比 | 18.4% | -1.8% |
| 净利润同比 | -55.9% | -75.2% |
| 每股收益（稀释后） | $0.20 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMARMAX
| Q4 25 | $139.2M | $71.1M | ||
| Q3 25 | $134.2M | $73.2M | ||
| Q2 25 | $122.0M | $72.8M | ||
| Q1 25 | $114.8M | $74.5M | ||
| Q4 24 | $117.5M | $72.5M | ||
| Q3 24 | $119.8M | $78.5M | ||
| Q2 24 | $107.2M | $78.5M | ||
| Q1 24 | $81.9M | $78.3M |
净利润ADMARMAX
| Q4 25 | $49.4M | $1.4M | ||
| Q3 25 | $36.4M | $4.0M | ||
| Q2 25 | $34.2M | $4.7M | ||
| Q1 25 | $26.9M | $-2.0M | ||
| Q4 24 | $111.9M | $5.8M | ||
| Q3 24 | $35.9M | $966.0K | ||
| Q2 24 | $32.1M | $3.7M | ||
| Q1 24 | $17.8M | $-3.4M |
毛利率ADMARMAX
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
营业利润率ADMARMAX
| Q4 25 | 45.1% | 13.1% | ||
| Q3 25 | 38.0% | 25.0% | ||
| Q2 25 | 35.1% | 19.3% | ||
| Q1 25 | 30.4% | 7.2% | ||
| Q4 24 | 32.6% | 5.9% | ||
| Q3 24 | 33.1% | 19.4% | ||
| Q2 24 | 36.6% | 20.6% | ||
| Q1 24 | 26.7% | 5.8% |
净利率ADMARMAX
| Q4 25 | 35.5% | 2.0% | ||
| Q3 25 | 27.1% | 5.4% | ||
| Q2 25 | 28.1% | 6.4% | ||
| Q1 25 | 23.4% | -2.6% | ||
| Q4 24 | 95.2% | 8.0% | ||
| Q3 24 | 30.0% | 1.2% | ||
| Q2 24 | 29.9% | 4.7% | ||
| Q1 24 | 21.7% | -4.3% |
每股收益（稀释后）ADMARMAX
| Q4 25 | $0.20 | — | ||
| Q3 25 | $0.15 | — | ||
| Q2 25 | $0.14 | — | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.45 | — | ||
| Q3 24 | $0.15 | — | ||
| Q2 24 | $0.13 | — | ||
| Q1 24 | $0.08 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $118.7M |
| 总债务越低越好 | $72.1M | $432.2M |
| 股东权益账面价值 | $477.3M | $452.4M |
| 总资产 | $624.2M | $582.5M |
| 负债/权益比越低杠杆越低 | 0.15× | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资ADMARMAX
| Q4 25 | $87.6M | $118.7M | ||
| Q3 25 | $61.4M | $107.5M | ||
| Q2 25 | $90.3M | $94.3M | ||
| Q1 25 | $71.6M | $89.1M | ||
| Q4 24 | $103.1M | $96.6M | ||
| Q3 24 | $86.7M | $83.8M | ||
| Q2 24 | $88.2M | $66.1M | ||
| Q1 24 | $45.3M | $82.1M |
总债务ADMARMAX
| Q4 25 | $72.1M | $432.2M | ||
| Q3 25 | $72.4M | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | $72.3M | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
股东权益ADMARMAX
| Q4 25 | $477.3M | $452.4M | ||
| Q3 25 | $431.2M | $448.1M | ||
| Q2 25 | $398.3M | $442.4M | ||
| Q1 25 | $373.4M | $433.5M | ||
| Q4 24 | $349.0M | $429.5M | ||
| Q3 24 | $231.9M | $423.1M | ||
| Q2 24 | $188.3M | $418.4M | ||
| Q1 24 | $153.7M | $412.0M |
总资产ADMARMAX
| Q4 25 | $624.2M | $582.5M | ||
| Q3 25 | $568.7M | $582.2M | ||
| Q2 25 | $558.4M | $574.8M | ||
| Q1 25 | $510.6M | $571.4M | ||
| Q4 24 | $488.7M | $581.6M | ||
| Q3 24 | $390.6M | $578.6M | ||
| Q2 24 | $376.4M | $571.4M | ||
| Q1 24 | $350.9M | $566.7M |
负债/权益比ADMARMAX
| Q4 25 | 0.15× | 0.96× | ||
| Q3 25 | 0.17× | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | 0.21× | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $33.5M |
| 自由现金流率自由现金流/营收 | 24.8% | 47.1% |
| 资本支出强度资本支出/营收 | 0.8% | 10.4% |
| 现金转化率经营现金流/净利润 | 0.72× | 28.39× |
| 过去12个月自由现金流最近4个季度 | $27.8M | $56.8M |
8季度趋势，按日历期对齐
经营现金流ADMARMAX
| Q4 25 | $35.6M | $40.9M | ||
| Q3 25 | $13.3M | $17.7M | ||
| Q2 25 | $21.1M | $4.6M | ||
| Q1 25 | $-19.7M | $5.7M | ||
| Q4 24 | $50.2M | $59.7M | ||
| Q3 24 | $25.0M | $17.6M | ||
| Q2 24 | $45.6M | $15.9M | ||
| Q1 24 | $-2.2M | $9.4M |
自由现金流ADMARMAX
| Q4 25 | $34.6M | $33.5M | ||
| Q3 25 | $-1.1M | $16.4M | ||
| Q2 25 | $18.7M | $2.9M | ||
| Q1 25 | $-24.4M | $4.0M | ||
| Q4 24 | $47.5M | $53.0M | ||
| Q3 24 | $24.0M | $16.3M | ||
| Q2 24 | $43.6M | $14.0M | ||
| Q1 24 | $-4.6M | $6.8M |
自由现金流率ADMARMAX
| Q4 25 | 24.8% | 47.1% | ||
| Q3 25 | -0.8% | 22.4% | ||
| Q2 25 | 15.3% | 4.0% | ||
| Q1 25 | -21.2% | 5.3% | ||
| Q4 24 | 40.4% | 73.2% | ||
| Q3 24 | 20.0% | 20.8% | ||
| Q2 24 | 40.7% | 17.8% | ||
| Q1 24 | -5.6% | 8.6% |
资本支出强度ADMARMAX
| Q4 25 | 0.8% | 10.4% | ||
| Q3 25 | 10.7% | 1.8% | ||
| Q2 25 | 2.0% | 2.2% | ||
| Q1 25 | 4.1% | 2.3% | ||
| Q4 24 | 2.3% | 9.1% | ||
| Q3 24 | 0.9% | 1.7% | ||
| Q2 24 | 1.9% | 2.4% | ||
| Q1 24 | 2.9% | 3.3% |
现金转化率ADMARMAX
| Q4 25 | 0.72× | 28.39× | ||
| Q3 25 | 0.36× | 4.45× | ||
| Q2 25 | 0.62× | 0.97× | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | 10.28× | ||
| Q3 24 | 0.70× | 18.22× | ||
| Q2 24 | 1.42× | 4.29× | ||
| Q1 24 | -0.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
